PRNewsWire
01 Jul 2026, 01:07 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is accused of using channel stuffing and undisclosed related party transactions to artificially inflate revenue and growth figures. — Allegations of accounting fraud and revenue manipulation strike at the core of a company's financial integrity and usually lead to significant valuation resets.
-0.90A securities fraud class action lawsuit has been filed against ADMA Biologics for materially false and misleading statements between August 2024 and March 2026. — Legal proceedings introduce significant contingent liabilities and regulatory risk, further depressing investor confidence.
-0.60A Culper Research report alleged that ADMA's reported 2025 growth of 20% was actually -3% in real terms. — A massive discrepancy between reported and actual growth suggests the company's fundamental business trajectory is far worse than previously believed.
-0.50Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a securities fraud class action lawsuit following allegations of channel stuffing and undisclosed related party transactions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Globe News Wire
1h ago
